产品展示更多>>
- ICG-001 780757-88-2；847591-62-2
- ICG-001 780757-88-2；847591-62-2
ICG-001 780757-88-2；847591-62-2
产品描述 描述 ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro
纯度 >98%储存/保存方法 Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.基本信息 别名 ICG001；ICG 001外观 Off-white powder可溶性/溶解性 DMSO ：100 mg/mL (182.27 mM)
Ethanol ：10 mg/mL (18.22 mM)生物活性 靶点 Wnt/β-cateninIn vitro(体外研究) PRI-724 binds specifically to CBP but not the related transcriptional coactivator p300, thereby disrupting the interaction of CBP with β-catenin. Treatment with PRI-724 selectively induces apoptosis in colon carcinoma cells but not in normal colonic epithelial cells and reduces in vitro growth of colon carcinoma cells.In vivo(体内研究) PRI-724 exhibits antitumor activity in the mouse xenograft models of colon cancer. The initial results of the Phase I clinic trial of PRI-724 has been disclosed publically. The drug exhibits an acceptable toxicity profile with only one dose-limiting toxicity of grade 3 reversible hyperbilirubinaemia. An Open-Label dose-escalation phase I/II study of PRI-724 for patients with advanced myeloid malignancies is still ongoing.研究领域 研究领域 EpigeneticsDrug DiscoverySmall Molecule DrugLead Compound DiscoveryICG-001 780757-88-2；847591-62-2温馨提示：本产品仅作科研实验使用，不支持临床等研究